Revised forecast
Fiscal year ending April 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Based on the assumption that strong sales of hemostatic agents in the U.S. gastrointestinal endoscopy market will continue, the company plans higher revenue and earnings for the full fiscal year ending April 2027. In Japan, revenue is expected to decline 12% year on year, reflecting factors including rejected insurance reimbursement claims.
Impairment loss ¥40.638 million, litigation settlement payment ¥12 million, total extraordinary losses ¥52.638 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → 13,422 Millions of yen |
| Operating profit | Not disclosed → 1,652 Millions of yen |
| Ordinary income | Not disclosed → 1,640 Millions of yen |
| Profit attributable to owners of the parent | Not disclosed → 1,590 Millions of yen |
| Net income per share | Not disclosed → 12.42 yen and sen |
| Fiscal Period Covered | Fiscal year ending April 2027 |
| Period Covered | Full year |
| Previous-period results | Net sales ¥10,886 million, operating income ¥1,335 million, ordinary income ¥3,971 million, net income attributable to owners of the parent ¥4,155 million, and basic earnings per share ¥34.89 |
| Reason for the revision | Based on the assumption that strong sales of hemostatic agents in the U.S. gastrointestinal endoscopy market will continue, the company plans higher revenue and earnings for the full fiscal year ending April 2027. In Japan, revenue is expected to decline 12% year on year, reflecting factors including rejected insurance reimbursement claims. |
| Details and amount of extraordinary loss | Impairment loss ¥40.638 million, litigation settlement payment ¥12 million, total extraordinary losses ¥52.638 million |
| Dividend forecast revision | The annual dividend forecast for the fiscal year ending April 2027 is ¥0.00, including a year-end dividend of ¥0.00. There is no explicit statement that the dividend forecast was revised. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended April 2026, product sales, primarily in the U.S. gastrointestinal endoscopy market, exceeded plan, while ¥2,661 million in foreign exchange gains resulting from the weaker yen also boosted ordinary income and below. For the fiscal year ending April 2027, the company plans higher revenue on the assumption that strong sales of hemostatic agents in the United States will continue, while forecasting lower revenue in Japan due in part to rejected insurance reimbursement claims.